Roche (RHHBY) sent a letter dated March 31 to the World Duchenne Organization stating the European Medicines Agency requested a temporary clinical hold on three studies involving Sarepta’s (SRPT) Duchenne muscular dystrophy gene therapy Elevidys after a 16-year-old boy who received the treatment died. “We are pausing enrollment and dosing of participants in these studies at EU country study sites, as well as the UK for the Roche-sponsored ENVOL study. Patient safety monitoring for already enrolled participants and ongoing collection of data will continue,” Roche added. Shares of Sarepta are down 9% to $56.86 in premarket trading.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRPT:
- Positive Outlook for Sarepta Therapeutics Amid Elevidys Trial Hold and Strong Market Position
- Sarepta price target lowered to $70 from $99 at Deutsche Bank
- Paramount downgraded, Broadcom upgraded: Wall Street’s top analyst calls
- Sarepta upgraded to Neutral from Sell at H.C. Wainwright
- Marks’ Resignation Is a ‘Blow for Biotech Industry,’ Says RBC Analyst as Biotech Stocks Fall